HighTide Therapeutics
- Biotech or pharma, therapeutic R&D
HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for chronic metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in late stage clinical development for the treatment of T2DM, MASH,and PSC with all studies having met their primary endpoints. HTD1801 in combination with GLP-1 RAs for the treatment of obesity is also being evaluated. HTD1801 has received Fast Track designation from the U.S. FDA for both MASH and PSC. HTD1801 has been included in the National Major New Drug Innovation Program.
Along with HTD1801, we have developed a strong pipeline of innovative product candidates comprising HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting nine potential indications collectively.
For more information, please visit www.hightidetx.com.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}